Clinical Trials Browser

Meningioma × pembrolizumab × 90 days × Clear all

NCT03279692 2026-01-29

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Phase 2 Active not recruiting

26 enrolled 14 charts

Meningioma